

NCT02560766 Raw comparison:

Summary:
CHIA has 17 criteria while your personal folder has 34 criteria
Total found criteria: 11/17
Total not Found: 6/17
Total Extra: 17
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male and female adolescent patients aged 13 to 17  │ Male and female adolescent patients aged 13 to 17  │
│ years diagnosed with RLS based on the IRLSSG       │ years diagnosed with RLS based on the IRLSSG       │
│ consensus criteria (Allen RP 2014) (Appendix 2)    │ consensus criteria (Allen RP 2014) (Appendix 2)    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total RLS severity score of 15 or greater on the   │ Total RLS severity score of 15 or greater on the   │
│ IRLS rating scale at Visit 1 (screening) and at    │ IRLS rating scale at Visit 1 (screening) and at    │
│ Visit 2 (baseline) (Appendix 8)                    │ Visit 2 (baseline) (Appendix 8)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ RLS symptoms for at least 4 of 7 consecutive       │ RLS symptoms for at least 4 of 7 consecutive       │
│ evenings/nights during the screening period        │ evenings/nights during the screening period        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Estimated creatinine clearance of at least 60      │ Estimated creatinine clearance of at least 60      │
│ mL/min (using the Cockcroft-Gault equation) at     │ mL/min (using the Cockcroft-Gault equation) at     │
│ screening only                                     │ screening only                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Signed patient and parent Institutional Review     │ Signed patient and parent Institutional Review     │
│ Board (IRB)-approved informed consent/assent form  │ Board (IRB)-approved informed consent/assent form  │
│ (as applicable) before any study-related           │ (as applicable) before any study-related           │
│ procedures are performed                           │ procedures are performed                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of a primary sleep disorder other than RLS │ History of a primary sleep disorder other than RLS │
│ that may significantly affect the symptoms of RLS  │ that may significantly affect the symptoms of RLS  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum ferritin level < 20 ng/mL at screening       │ Serum ferritin level \< 20 ng/mL at screening      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of allergy hypersensitivity or intolerance │ History of allergy hypersensitivity or intolerance │
│ to HORIZANT or any other gabapentin products (eg   │ to HORIZANT or any other gabapentin products (e g  │
│ Neurontin® Gralise®)                               │ Neurontin® Gralise®)                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Currently meet Diagnostic and Statistical Manual   │ Currently meet Diagnostic and Statistical Manual   │
│ of Mental Disorders - Fifth Edition (DSM-5)        │ of Mental Disorders - Fifth Edition (DSM-5)        │
│ criteria for substance use disorder or history     │ criteria for substance use disorder or history     │
│ thereof within 12 months before dosing             │ thereof within 12 months before dosing             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current or past history of any significant         │ Current or past history of any significant         │
│ psychiatric disorder including but not limited to  │ psychiatric disorder including but not limited to  │
│ depression (treatment with antidepressants)        │ depression (treatment with antidepressants)        │
│ bipolar disorder or schizophrenia                  │ bipolar disorder or schizophrenia                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Medical condition or disorder that would interfere │ Medical condition or disorder that would interfere │
│ with the action absorption distribution metabolism │ with the action absorption distribution metabolism │
│ or excretion of gabapentin enacarbil or in the     │ or excretion of gabapentin enacarbil or in the     │
│ investigator's judgment is considered to be        │ Principal Investigator's judgment is considered to │
│ clinically significant and may pose a safety       │ be clinically significant and may pose a safety    │
│ concern or could interfere with the accurate       │ concern or could interfere with the accurate       │
│ assessment of safety or efficacy or could          │ assessment of safety or efficacy or could          │
│ potentially affect a patient's safety or study     │ potentially affect a patient's safety or study     │
│ outcome                                            │ outcome                                            │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Body weight greater than 33 4 kg and a healthy weight using age-based body mass index (BMI) range    │
│ 5th-85th percentile at screening and baseline Appendix 3 contains BMI-for-age charts that can be     │
│ consulted                                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Suffering from a movement disorder that could mimic or confound the accurate diagnosis of RLS (eg    │
│ Tourette's syndrome tic disorder periodic limb movement disorder [PLMD] sleep disorders)             │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Diagnosis of attention-deficit hyperactivity disorder (ADHD) is allowed provided the patient is not  │
│ receiving medication(s) known to affect the assessment of RLS                                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ History of suicidal behavior or suicidal ideation as indicated by the C-SSRS administered at         │
│ screening (the questionnaire is provided in Appendix 4) and as per investigator's judgment           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ History of seizure disorder or at increased risk for development of a seizure disorder including but │
│ not limited to complicated febrile seizure and history of significant head injury                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Clinically significant abnormal laboratory result or physical examination finding not resolved by    │
│ the time of baseline assessments                                                                     │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ In the judgement of the Principal Investigator clinically significant abnormal laboratory result or  │
│ physical examination finding not resolved by the time of baseline assessments                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ History of suicidal behavior or suicidal ideation as indicated by the C-SSRS administered at         │
│ screening and as per investigator's judgment                                                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Diagnosis of ADHD is allowed provided the patient is not receiving medication(s) known to affect the │
│ assessment of RLS                                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 13 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Positive test for hepatitis B surface antigen (HBsAg) hepatitis C virus (HCV) antibody human         │
│ immunodeficiency virus (HIV) antibody at screening                                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Male patients must agree to use a barrier method (male condom female condom diaphragm or cervical    │
│ cap) with spermicide for at least 30 days prior to dosing and throughout the study if sexually       │
│ active Male patients who normally abstain from sexual activity may be recruited providing they       │
│ remain abstinent during the study or if they become sexually active they must agree to use a barrier │
│ method as described above                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Negative pregnancy test for all females at screening and baseline Sexually active patients must      │
│ agree to use 2 medically accepted methods of contraception 1 of which is a highly effective method   │
│ (e g hormonal or intrauterine device \[IUD\]) \[the second may be a barrier method (e g male condom  │
│ female condom diaphragm or cervical cap)\] during the course of the study treatment and for 4 weeks  │
│ after the last dose of study treatment For patients using hormonal contraceptives as one of the      │
│ methods the contraceptive should be stabilized for at least 3 months prior to screening              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patients with a history of epilepsy subjects currently prescribed treatments for epilepsy or         │
│ subjects with a history of seizure in the last 5 years                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Received an investigational product within 6 months prior to dosing                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Willing and able to follow the study procedures                                                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Uncontrolled hypertension defined as blood pressure (BP) ≥ 95 percentile adjusted for age height and │
│ sex according to the tables published by the US Department of Health and Human Services 2005 at      │
│ screening and before dosing Appendix 5 contains the tables that can be consulted                     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female patients who normally abstain from sexual activity may be recruited providing they remain     │
│ abstinent during the study or if they become sexually active they must agree to use 2 effective      │
│ methods of birth control as described above                                                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Body weight greater than 33 4 kg and a healthy weight using age-based body mass index (BMI) range    │
│ 5th-95th percentile at screening and baseline                                                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Participated in an investigational drug trial within the 4 weeks before dosing or plans to           │
│ participate in another study at any time during this study                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Appropriate cognitive and communication skills as judged by the clinician needed to complete study   │
│ assessments                                                                                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 17 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Suffering from an isolated periodic limb movement disorder without RLS                               │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛